Testing light and sound brain stimulation in adults with Down syndrome
Tests light and sound brain stimulation in adults with Down syndrome.
Key facts
- Who runs it
- Massachusetts Institute of Technology
- Where
- Cambridge, United StatesSee the site
- Trial code
- Registry title
- Gamma Frequency Stimulation in Individuals With Down Syndrome
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 6 Dec 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 4 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- GENUS device (Active Settings)
- GENUS device (Sham Settings)
- Record updated
- 31 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Down syndrome and cognitively normal adult controls. It tests light, sound and touch stimulation of the brain.
- Age
- 25 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Adults with Down syndrome confirmed by a doctor; mosaic Down syndrome is not accepted.
- Earlier treatment
- Medically stable, with medications unchanged for the past 3 months.
Main reasons for not taking part
- Mosaic Down syndrome, or both Down syndrome and Autism
- Seizure or epilepsy in the past 24 months, or taking anti-epileptic drugs
- Stroke in the past 24 months, or a history of migraine headache
- An active implanted device such as a pacemaker or deep brain stimulator
- Pregnancy (self-reported)
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Subject is between the ages of 25-65
- Subject must have a clinically confirmed diagnosis of Down Syndrome (karyotypes optional). Individuals with mosaic Down syndrome will be excluded
- Subject or their legal guardian is willing to sign informed consent document
- If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent
- Subject will be medically stable with consistent medication over the previous 3 months
Who cannot take part
- Active treatment with one or more anti-epileptic agent
- Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc)
- Subjects has history of a dual diagnosis Down Syndrome and Autism
- Subjects with has history of seizure or epilepsy within the past 24 months
- Subjects with a new diagnosis of Attention-deficit/hyperactivity disorder (ADHD) (< 6 months) or untreated ADHD
- Subjects who have a known history a stroke within the past 24 months
- Subjects with a known history of migraine headache
- Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc
- Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator
- Subjects who have profound and uncorrected hearing or visual impairment
- Subjects with clinically significant suicide risk and/or suicide attempt in the past 1 year
- Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol
- Subjects who are pregnant (self-report)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
Where in United States
- Massachusetts Institute of TechnologyCambridge, United StatesContact: Ana Trisini Lipsanopoulos, BSTaking people
About the trial
What the trial wants to find out
Down Syndrome (DS) is characterized by an additional copy of chromosome 21, which also increases risk of Alzheimer's Disease (AD). The investigators' lab found a non-invasive way to remove toxic proteins from the brain in AD mouse models. Remarkably, treated mice also have improved memory on behavioral testing. The investigators then translated this non-invasive method, which uses light and sound to stimulate the brain, to be used in mild Alzheimer's patients and cognitively normal adults. The investigators have also translated this research into a vibrating speaker device to study tactile vibration to stimulate the brain as well. For the present study, 30 participants with Down Syndrome and 30 cognitively normal adult controls will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) during light, sound, and tactile stimulation. The investigators will also test for safety, feasibility, and cognitive performance before and after a 30-60 minute session of light and sound stimulation to optimize the stimulation devices for use in the DS population.
The 4 groups in the trial
- Down Syndrome ExperimentalTreatment being tested
Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.
Treatment: GENUS device (Active Settings)
- Down Syndrome ShamSham treatment, for comparison
Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.
Treatment: GENUS device (Sham Settings)
- Cognitively Normal ExperimentalTreatment being tested
Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.
Treatment: GENUS device (Active Settings)
- Cognitively Normal ShamSham treatment, for comparison
Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.
Treatment: GENUS device (Sham Settings)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Acute Exposure of Individuals With Down Syndrome to Gamma Frequency Stimulation
- Plain-language title
- Testing light and sound brain stimulation in adults with Down syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05196984, who can take part
- Record updated
- 31 March 2026